AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A hybrid antigen comprising at least one antigenic domain of an infectious agent or tumor antigen, at least one binding domain that non-covalently binds to a heat shock protein, and at least one peptide linker there between selected from the group consisting of Phe Phe Arg Lys (FFRK; SEQ ID NO:699); Phe Arg Lys (FRK); Phe Arg Lys Asn (FRKN, SEQ ID NO:701); Arg Lys Asn (RKN); Phe Phe Arg Lys Asn (FFRKN, SEQ ID NO:702); Phe Arg (FR), Gln Leu Lys (QLK), Gln Leu Glu (QLE), Ala Lys Val Leu (AKVL; SEQ ID NO:700); Lys Asn (KN); Arg Lys (RK); ~~or~~ and AA_1-AA_2-AA_3-leucine (SEQ ID NO:9), wherein ~~AA1~~ AA_1 is ~~A, S, V, E, G, L, or K~~ Ala, Ser, Val, Glu, Gly, Leu, or Lys, ~~AA2~~ AA_2 is ~~K, V, or E~~ Lys, Val, or Glu; and ~~AA3~~ AA_3 is ~~V, S, F, K, A, E, or T~~ Val, Ser, Phe, Lys, Ala, Glu, or Thr.

2. (currently amended) A composition ~~for inducing an immune response to an infectious agent or tumor antigen~~ comprising at least one hybrid antigen of Claim 1 and a pharmaceutically acceptable carrier.

3. (currently amended) A composition ~~for inducing an immune response to an infectious agent or tumor antigen~~ comprising a non-covalent complex of at least one heat shock protein and at least one hybrid antigen of Claim 1 and a pharmaceutically acceptable carrier.

4. (currently amended) The composition of ~~claim~~ Claim 3 wherein the heat shock protein is a hsp70 family member.

5. (currently amended) A method for inducing an immune response in a subject to an infectious agent ~~or tumor antigen~~ comprising administering to ~~a~~ the subject at least one hybrid antigen of Claim 1, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent.

6. (currently amended) A method for inducing an immune response in a subject to an infectious agent ~~or tumor antigen~~ comprising administering to ~~a~~ the subject a complex of:

(a) ~~a~~ at least one hybrid antigen of Claim 1, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent; and

(b) ~~a~~ at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

7. (currently amended) The method of ~~claim~~ Claim 6 wherein the heat shock protein is a hsp70 family member.

8. (currently amended) A method for treating an infectious disease ~~or cancer~~ comprising administering to a subject having an infectious disease at least one hybrid antigen of Claim 1, ~~wherein at least one antigenic domain is from the infectious disease or cancer~~, which said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent is associated with said infectious disease.

9. (currently amended) A method for treating an infectious disease ~~or cancer~~ comprising administering to a subject having an infectious disease a complex of:

(a) ~~a~~ at least one hybrid antigen of Claim 1, ~~wherein at least one antigenic domain is from the infectious disease or cancer~~, wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent is associated with said infectious disease; and

(b) ~~a~~ at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

10. (currently amended) The method of ~~claim~~ Claim 9 wherein the heat shock protein is a hsp70 family member.

11. (currently amended) A hybrid antigen consisting essentially of at least one antigenic domain of an infectious agent or tumor antigen, at least one binding domain that non-

covalently binds to a heat shock protein, and at least one peptide linker there between, ~~and~~ wherein said peptide linker is selected from the group consisting of Phe Phe Arg Lys (FFRK; SEQ ID NO:699); Phe Arg Lys (FRK); Phe Arg Lys Asn (FRKN, SEQ ID NO:701); Arg Lys Asn (RKN); Phe Phe Arg Lys Asn (FFRKN, SEQ ID NO:702); Phe Arg (FR), Gln Leu Lys (QLK), Gln Leu Glu (QLE), Ala Lys Val Leu (AKVL; SEQ ID NO:700); Lys Asn (KN); Arg Lys (RK); ~~or~~ and AA_1-AA_2-AA_3-leucine (SEQ ID NO:9), wherein ~~AA1~~ AA_1 is ~~A, S, V, E, G, L, or K~~ Ala, Ser, Val, Glu, Gly, Leu, or Lys, ~~AA2~~ AA_2 is ~~K, V, or E~~ Lys, Val, or Glu; and ~~AA3~~ AA_3 is ~~V, S, F, K, A, E, or T~~ Val, Ser, Phe, Lys, Ala, Glu, or Thr.

12. (currently amended) A composition ~~for inducing an immune response to an infectious agent or tumor antigen~~ comprising at least one hybrid antigen of Claim 11, and a pharmaceutically acceptable carrier.

13. (currently amended) A composition ~~for inducing an immune response to an infectious agent or tumor antigen~~ comprising a complex of least one heat shock protein and at least one hybrid antigen of Claim 11 and a pharmaceutically acceptable carrier.

14. (currently amended) The composition of ~~claim~~ Claim 13 wherein the heat shock protein is a hsp70 family member.

15. (currently amended) A method for inducing an immune response in a subject to an infectious agent ~~or tumor antigen~~ comprising administering to ~~a~~ the subject at least one hybrid antigen of Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent.

16. (currently amended) A method for inducing an immune response in a subject to an infectious agent ~~or tumor antigen~~ comprising administering to ~~a~~ the subject a complex of:

(a) ~~a~~ at least one hybrid antigen of Claim 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said infectious agent; and

(b) ~~a~~ at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

17. (currently amended) The method of ~~claim~~ Claim 15 wherein the heat shock protein is a hsp70 family member.

18. (currently amended) A method for treating an infectious disease ~~or cancer~~ comprising administering to a subject having an infectious disease at least one hybrid antigen of Claim 11, ~~wherein at least one antigenic domain is from the infectious disease or cancer~~ wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent is associated with said infectious disease.

19. (currently amended) A method for treating an infectious disease ~~or cancer~~ comprising administering to a subject having an infectious disease a complex of:

(a) ~~a~~ at least one hybrid antigen of Claim ~~1~~ 11, ~~wherein the antigenic domain is from the infectious disease or cancer~~ wherein said at least one hybrid antigen comprises at least one antigenic domain of an infectious agent, and wherein said infectious agent is associated with said infectious disease; and

(b) ~~a~~ at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

20. (currently amended) The method of claim 18 wherein the heat shock protein is a hsp70 family member.

21. (previously presented) A peptide that is Phe Phe Arg Lys (FFRK; SEQ ID NO:699); Phe Arg Lys (FRK); Phe Arg Lys Asn (FRKN, SEQ ID NO:701); Arg Lys Asn (RKN); Phe Phe Arg Lys Asn (FFRKN, SEQ ID NO:702); Phe Arg (FR), Gln Leu Lys (QLK), Gln Leu Glu (QLE), Ala Lys Val Leu (AKVL; SEQ ID NO:700); Lys Asn (KN); Arg Lys (RK); or AA_1-AA_2-AA_3-leucine (SEQ ID NO:9), wherein AA1 is A, S, V, E, G, L, or K, AA2 is K, V, or E; and AA3 is V, S, F, K, A, E, or T.

22. (new) A method for inducing an immune response in a subject to a tumor antigen comprising administering to the subject at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen.

23. (new) A method for inducing an immune response in a subject to a tumor antigen comprising administering to a subject a complex of:

(a) at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen; and

(b) at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

24. (new) The method of claim 23 wherein the heat shock protein is a hsp 70 family member.

25. (new) A method for treating cancer comprising administering to a subject having a cancer at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen, and wherein said tumor antigen is associated with said cancer.

26. (new) A method for treating cancer comprising administering to a subject having a cancer a complex of:

(a) at least one hybrid antigen of Claim 1 or 11, wherein said at least one hybrid antigen comprises at least one antigenic domain of said tumor antigen, and wherein said tumor antigen is associated with said cancer; and

(b) at least one heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

27. (new) The method of Claim 26 wherein the heat shock protein is a hsp70 family member.

28. (new) The hybrid antigen of Claim 1 or 11, wherein said hybrid antigen is in the range of 10-500 amino acids.

29. (new) The hybrid antigen of Claim 1 or 11, wherein said antigenic domain is of an infectious agent.

30. (new) The hybrid antigen of Claim 1 or 11, wherein said antigenic domain is of a tumor antigen associated with a neoplastic disease.

31. (new) The hybrid antigen of Claim 30, wherein the neoplastic disease is selected from the group consisting of sarcoma, lymphoma, leukemia, melanoma, carcinoma of the breast, carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix, uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma, and astrocytoma.

32. (new) The hybrid antigen of Claim 29, wherein the infectious agent is selected from the group consisting of a bacterium, a virus, a protozoan, a mycoplasma, a fungus, a yeast, a parasite, and a prion.

33. (new) The hybrid antigen of Claim 32, wherein the infectious agent is a bacterium.

34. (new) The hybrid antigen of Claim 33, wherein the bacterium is selected from the group consisting of *Salmonella, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Escherichia, Klebsiella, Vibrio, Mycobacterium,* and *Mycoplasma pneumoniae.*

35. (new) The hybrid antigen of Claim 32, wherein the infectious agent is a virus.

36. (new) The hybrid antigen of Claim 35, wherein the virus is selected from the group consisting of a human papilloma virus, herpes virus, retrovirus, hepatitis virus, influenza virus, rhinovirus, respiratory syncytial virus, cytomegalovirus, adenovirus, herpes simplex virus, herpes zoster virus, human immunodeficiency virus 1, and human immunodeficiency virus 2.

37. (new) The hybrid antigen of Claim 32, wherein the infectious agent is a protozoan.

38. (new) The hybrid antigen of Claim 37, wherein the protozoan is selected from the group consisting of an amoeba, a malarial parasite, or *Trypanosoma cruzi.*

39. (new) The composition of Claim 4 or 14, wherein the hsp70 family member is BiP, hsp 70 or hsc70.

40. (new) The composition of Claim 3 or 13 further comprising one or more adjuvants.

41. (new) The composition of Claim 4 or 14 further comprising one or more adjuvants.

42. (new) A composition comprising a plurality of the hybrid antigen of Claim 1 or 11.

43. (new) The composition of claim 42 further comprising a plurality of heat shock proteins non-covalently complexed to the hybrid antigens.

44. (new) The method of claim 5, 6, 15 or 16 wherein the subject is a human.

45. (new) The method of claim 22 wherein the subject is a human.

46. (new) The method of claim 23 wherein the subject is a human.